Edgewood Management’s Seres Therapeutics MCRB Stock Holding History

Edgewood Management’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2,500	Closed	-$70K	–	81
2023 Q4	$70K	Hold	2,500	–	–	﹤0.01%	79
2023 Q3	$119K	Hold	2,500	–	–	﹤0.01%	77
2023 Q2	$240K	Sell	2,500 -2,500	-50%	-$272K	﹤0.01%	77
2023 Q1	$567K	Hold	5,000	–	–	﹤0.01%	67
2022 Q4	$560K	Hold	5,000	–	–	﹤0.01%	64
2022 Q3	$642K	Buy	+5,000	New	+$512K	﹤0.01%	57
2022 Q2	–	Sell	-3,500	Closed	-$498K	–	83
2022 Q1	$498K	Hold	3,500	–	–	﹤0.01%	69
2021 Q4	$583K	Buy	3,500 +500	+17%	+$79.4K	﹤0.01%	66
2021 Q3	$418K	Buy	3,000 +1,000	+50%	+$196K	﹤0.01%	72
2021 Q2	$954K	Buy	2,000 +750	+60%	+$316K	﹤0.01%	53
2021 Q1	$515K	Buy	+1,250	New	+$576K	﹤0.01%	69

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Edgewood Management's MCRB Position: Q1 2024 in Review

Edgewood Management sold out of Seres Therapeutics (MCRB) in Q1 2024, closing a stake of 2,500 shares — an estimated $70K sold.

Edgewood Management first reported a position in MCRB in Q1 2021 and held it in 11 quarters. The position peaked at $954K in Q2 2021. 99 funds tracked by Wall St. Rank hold MCRB as of Q1 2024.

Edgewood Management reported no remaining Seres Therapeutics position as of Q1 2024 after selling out during the quarter.
Edgewood Management sold 2,500 Seres Therapeutics shares in Q1 2024, an estimated $70K.
Edgewood Management first reported a position in Seres Therapeutics in Q1 2021 and held it in 11 quarters.
Edgewood Management's Seres Therapeutics position peaked at $954K in Q2 2021.
99 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2024.

Based on Edgewood Management's 13F filing for Q1 2024, filed 14 May 2024.